Algert Global LLC boosted its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 107.1% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 114,913 shares of the company's stock after acquiring an additional 59,420 shares during the quarter. Algert Global LLC owned 0.18% of Viridian Therapeutics worth $2,614,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Novo Holdings A S grew its stake in Viridian Therapeutics by 81.8% during the 2nd quarter. Novo Holdings A S now owns 2,000,000 shares of the company's stock valued at $26,020,000 after acquiring an additional 900,000 shares in the last quarter. Maverick Capital Ltd. grew its position in shares of Viridian Therapeutics by 22.9% in the second quarter. Maverick Capital Ltd. now owns 3,307,945 shares of the company's stock valued at $43,036,000 after purchasing an additional 615,531 shares in the last quarter. Candriam S.C.A. increased its holdings in shares of Viridian Therapeutics by 167.8% in the second quarter. Candriam S.C.A. now owns 749,804 shares of the company's stock valued at $9,754,000 after purchasing an additional 469,804 shares during the last quarter. Vanguard Group Inc. lifted its position in Viridian Therapeutics by 7.8% during the first quarter. Vanguard Group Inc. now owns 3,234,279 shares of the company's stock worth $56,632,000 after buying an additional 233,331 shares in the last quarter. Finally, Millennium Management LLC lifted its position in Viridian Therapeutics by 1,014.7% during the second quarter. Millennium Management LLC now owns 228,182 shares of the company's stock worth $2,969,000 after buying an additional 207,711 shares in the last quarter.
Wall Street Analyst Weigh In
A number of analysts have issued reports on the company. BTIG Research raised their target price on Viridian Therapeutics from $56.00 to $61.00 and gave the stock a "buy" rating in a research note on Thursday, September 26th. Needham & Company LLC reaffirmed a "buy" rating and set a $38.00 target price on shares of Viridian Therapeutics in a research note on Monday. Royal Bank of Canada reissued an "outperform" rating and issued a $44.00 price target on shares of Viridian Therapeutics in a research note on Thursday, September 19th. Oppenheimer restated an "outperform" rating and set a $28.00 price target (down previously from $31.00) on shares of Viridian Therapeutics in a report on Monday, August 12th. Finally, TD Cowen assumed coverage on Viridian Therapeutics in a report on Monday. They issued a "buy" rating on the stock. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat, Viridian Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $36.33.
Check Out Our Latest Stock Analysis on Viridian Therapeutics
Insider Transactions at Viridian Therapeutics
In other Viridian Therapeutics news, COO Thomas W. Beetham purchased 5,000 shares of the firm's stock in a transaction on Friday, September 27th. The stock was bought at an average cost of $23.41 per share, with a total value of $117,050.00. Following the acquisition, the chief operating officer now directly owns 6,000 shares of the company's stock, valued at approximately $140,460. This represents a 500.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Stephen F. Mahoney acquired 21,400 shares of the stock in a transaction dated Friday, September 27th. The shares were acquired at an average cost of $23.33 per share, with a total value of $499,262.00. Following the completion of the transaction, the chief executive officer now owns 21,400 shares in the company, valued at approximately $499,262. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 1,626,400 shares of company stock valued at $30,616,312. 0.65% of the stock is currently owned by corporate insiders.
Viridian Therapeutics Trading Down 0.2 %
Viridian Therapeutics stock traded down $0.04 during midday trading on Wednesday, reaching $21.87. 687,881 shares of the stock traded hands, compared to its average volume of 1,119,097. The firm has a market cap of $1.73 billion, a PE ratio of -5.07 and a beta of 1.10. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04. The company has a 50-day simple moving average of $22.73 and a two-hundred day simple moving average of $17.30. Viridian Therapeutics, Inc. has a 12-month low of $11.40 and a 12-month high of $27.20.
Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) earnings per share for the quarter, missing analysts' consensus estimates of ($1.11) by ($0.04). The business had revenue of $0.09 million during the quarter, compared to analyst estimates of $0.08 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. Research analysts expect that Viridian Therapeutics, Inc. will post -4.04 earnings per share for the current fiscal year.
Viridian Therapeutics Profile
(
Free Report)
Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.
Further Reading
Before you consider Viridian Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viridian Therapeutics wasn't on the list.
While Viridian Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.